Vivesto AB
OASMY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.42K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $27,420.00 |
|---|---|
| Enterprise Value | $-1,752,580.00 |
| Earnings per Share | $-0.48 |
| Beta | 1.75 |
| Outstanding Shares | 274,196,666 |
Return
| Return on Equity | -14.64% |
|---|---|
| Return on Assets | -13.75% |
| Return on Invested Capital | -19.80% |
Valuation & Multiples
| P/E Ratio | -8.8 |
|---|---|
| PEG | 73.35 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.15 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$169,232
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Vivesto AB
4 employees
CEO: Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products port...